Mucolife Therapeutics AB - Modern mucolytic that dissolves accumulated mucus plugs from the lungs

MucoLife Therapeutics is revolutionizing the treatment of pulmonary mucus obstruction in Chronic obstructive pulmonary disease (COPD) and Cytstic Fibrosis (CF). Our lead product is a true mucolytic that dissolves mucus plugs obstructing the airways.

Impact: COPD affects 16 million in the US, 400 million globally, and is the third leading cause of death. 60% patients have a mucus plug disease subtype, where mucus accumulation leads to airway obstruction and irreversible lung damage. Current treatment options fail to address mucus plugs, leaving a critical gap in COPD patient care

CEO: Thaher Pelaseyed

GUV conctact: Anders Waas